CR61 Obstipation as a manifestation of bilateral hydronephrosis
Marina Andrešića, Nikolina Novakb, Josipa Živkoc, Maša Sorića

a Emergency Medicine Department, University Hospital Dubrava, Zagreb, Croatia

DOI: https://doi.org/10.26800/LV-145-supl2-CR61

Marina Andrešić 0000-0002-3753-778X, Nikolina Novak 0000-0001-7416-7805, Josipa Živko 0000-0001-7297-5366, Maša Sorić 0000-0002-5002-9800

KEYWORDS: Hydronephrosis; Ultrasound; Intestinal Obstruction

INTRODUCTION/OBJECTIVES: Hydronephrosis is a progressive dilatation of the renal calyces due to obstruction of urine outflow. If left untreated, the disease progresses to kidney failure and death.

CASE PRESENTATION: A 59-year-old man presented to the emergency department with a 5-day history of obstipation and bloating. He had a permanent urinary catheter and had no complaints regarding it. Vital signs were normal. Physical examination revealed abdominal distension and diffuse abdominal tenderness without peritoneal guarding. Laboratory tests revealed elevated C-reactive protein (208.6mg/L), high creatinine (639μg/L), urea (30.5mmol/L), high white blood cell count (37.8x10(9)/L) with normal urinalysis. Immediately, point-of-care ultrasound was performed which revealed bilateral hydronephrosis (grade IV) and dilated small bowel loops with wall thickening, keyboard sign, and “to-and-fro” peristalsis, indicating small bowel obstruction. Abdominal computed tomography (CT) without contrast confirmed nephrolithiasis and bilateral ureterolithiasis without ileus due to a widespread prostatic neoplasm. A urologist was consulted and a bilateral percutaneous nephrostomy was performed and the patient was admitted for further treatment.

CONCLUSION: The purpose of this case report is to accentuate the importance of considering wide differential diagnoses in patients with abdominal symptoms and the benefit of point-of-care ultrasound in making the diagnoses, especially in patients not fit for contrast CT imaging.

CR62 Personalized approach to patients with statin intolerance based on pharmacogenomics (function of OATP1B1 protein)
Anja Ćukc, Doroteja Dedića, Dunja Leskovarb, Livija Šimićevićc

a School of Medicine, University of Zagreb, Zagreb, Croatia
b Division for Metabolic Diseases, Department of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia
c Division for Pharmacogenomics and Therapy Individualization, Department of Laboratory Diagnostics, University Hospital Centre Zagreb, Zagreb, Croatia

DOI: https://doi.org/10.26800/LV-145-supl2-CR62

Anja Ćuk 0000-0002-5992-8327, Doroteja Dedić 0000-0002-2811-4398, Dunja Leskovar 0000-0002-2342-4450, Livija Šimićević 0000-0002-2491-1920

KEYWORDS: dyslipidemia; hmg coa statins; OATP1B1 protein, human; pharmacogenomics

INTRODUCTION/OBJECTIVES: Statins, HMG CoA reductase inhibitors, are effective at lowering blood cholesterol levels and protecting against cardiovascular incidents. Their uptake into hepatocytes depends on the activity of the SLCO1B1 gene which codes for the OATP1B1 transporter protein. Pharmacogenomic testing provides us information about the activity level of a certain protein. Lowered activity level of OATP1B1 protein can prolong the bioavailability of some drugs, such as statins. This greater systemic exposure to statins carries a higher risk of intolerance symptoms when compared to normal function of the OATP1B1 protein.

CASE PRESENTATION: We present two patients with dyslipidemia and statin intolerance symptoms. Female, 58, with history of multiple cardiovascular incidents presented with elevated liver function tests (GGT 1048, ALP 167, AST 219, ALT 93) while on atorvastatin therapy. After removal of the statin, her LFTs improved (GGT 419, ALP 122, AST 80, ALT 98) which indicated statin-induced liver lesion. Male, 55, also with history of cardiovascular incidents presented with elevated liver function tests (GGT 1048, ALP 167, AST 219, ALT 93) while on atorvastatin therapy. After removal of the statin, her LFTs improved (GGT 419, ALP 122, AST 80, ALT 98) which indicated statin-induced liver lesion. Male, 55, also with history of cardiovascular incidents presented with elevated liver function tests (GGT 1048, ALP 167, AST 219, ALT 93) while on atorvastatin therapy. After removal of the statin, the liver LFTs improved (GGT 419, ALP 122, AST 80, ALT 98) which indicated statin-induced liver lesion. Male, 55, also with history of cardiovascular incidents presented with elevated liver function tests (GGT 1048, ALP 167, AST 219, ALT 93) while on atorvastatin therapy. After removal of the statin, the liver LFTs improved (GGT 419, ALP 122, AST 80, ALT 98) which indicated statin-induced liver lesion.

CONCLUSION: The example of these two patients shows us how pharmacogenomic testing can help in choosing the right therapy based on individuals’ genetics.